{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T23:41:55Z","timestamp":1793922115125,"version":"4.8.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"vor","delay-in-days":10,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.jtct.2026.03.040","type":"journal-article","created":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T23:16:21Z","timestamp":1778368581000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Infections in the First 30 Days after Chimeric Antigen Receptor T-Cell Therapy in Patients Not Receiving Fluoroquinolone Prophylaxis"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9561-3592","authenticated-orcid":false,"given":"Gemma K.","family":"Reynolds","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark R.","family":"Dowling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Valencia-Klug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin W.","family":"Teh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3515-0215","authenticated-orcid":false,"given":"Mary Ann","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinay","family":"Vanguru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon J.","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Joy","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8443-314X","authenticated-orcid":false,"given":"Monica A.","family":"Slavin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Thursky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2026.03.040_bib0001","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1182\/blood-2020-141210","article-title":"Antibiotic therapy and low gut microbiome diversity is associated with decreased response and high toxicity in BCP-ALL and DLBCL patients after treatment with CD19. CAR T-cells","volume":"136","author":"Blumenberg","year":"2020","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.jtct.2026.03.040_bib0002","doi-asserted-by":"crossref","DOI":"10.1111\/tid.14395","article-title":"Striking the right balance: navigating antimicrobial stewardship and antibiotic prescribing after CAR-T-cell therapy","volume":"26","author":"Reynolds","year":"2024","journal-title":"Transpl Infect Dis"},{"issue":"10","key":"10.1016\/j.jtct.2026.03.040_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2025.07.022","article-title":"Opportunities to improve antibiotic stewardship, and identification of blood biomarkers associated with bacteremia following CAR-T cell therapy","volume":"31","author":"Ng","year":"2025","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2026.03.040_bib0004","doi-asserted-by":"crossref","first-page":"6907","DOI":"10.1182\/blood-2023-181999","article-title":"First fever between lymphodepletion and day 30 after CAR-T cell therapy: patterns, origins, and implications in lymphoma patients","volume":"142","author":"Melica","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2026.03.040_bib0005","series-title":"Cytokine Release Syndrome (CRS)","year":"2025"},{"key":"10.1016\/j.jtct.2026.03.040_bib0006","series-title":"The EBMT\/EHA CAR-T Cell Handbook","author":"Kr\u00f6ger","year":"2022"},{"issue":"8","key":"10.1016\/j.jtct.2026.03.040_bib0007","doi-asserted-by":"crossref","first-page":"e573","DOI":"10.1016\/S2352-3026(22)00166-1","article-title":"[18F]FDG-PET-CT compared with CT for persistent or recurrent neutropenic fever in high-risk patients (PIPPIN): a multicentre, open-label, phase 3, randomised, controlled trial","volume":"9","author":"Douglas","year":"2022","journal-title":"Lancet Haematol"},{"issue":"1b","key":"10.1016\/j.jtct.2026.03.040_bib0008","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1445-5994.2010.02338.x","article-title":"Introduction to the Australian consensus guidelines for the management of neutropenic fever in adult cancer patients, 2010\/2011","volume":"41","author":"Lingaratnam","year":"2011","journal-title":"Intern Med J"},{"issue":"10","key":"10.1016\/j.jtct.2026.03.040_bib0009","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood.2023020578","article-title":"Immune effector cell\u2013associated hematotoxicity: EHA\/EBMT consensus grading and best practice recommendations","volume":"142","author":"Rejeski","year":"2023","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jtct.2026.03.040_bib0010","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004475","article-title":"The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R\/R LBCL","volume":"10","author":"Rejeski","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jtct.2026.03.040_bib0011","unstructured":"Teh BW, Mikulska M, Averbuch D, et al. Consensus position statement on advancing the standardised reporting of infection events in immunocompromised patients. The Lancet Infectious Diseases."},{"key":"10.1016\/j.jtct.2026.03.040_bib0012","series-title":"Device\u2011Associated Module 4: Bloodstream Infection Event (Central Line\u2011Associated Bloodstream Infection and Non\u2011Central Line Associated Bloodstream Infection)","year":"2025"},{"issue":"6","key":"10.1016\/j.jtct.2026.03.040_bib0013","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","article-title":"Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium","volume":"71","author":"Donnelly","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.jtct.2026.03.040_bib0014","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"24","key":"10.1016\/j.jtct.2026.03.040_bib0015","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1182\/blood.2020010543","article-title":"CAR-HEMATOTOX: a model for CAR T-cell\u2013related hematologic toxicity in relapsed\/refractory large B-cell lymphoma","volume":"138","author":"Rejeski","year":"2021","journal-title":"Blood"},{"issue":"01","key":"10.1016\/j.jtct.2026.03.040_bib0016","article-title":"Updated steroid conversion calculator","volume":"42025","author":"Lundholm","year":"2025","journal-title":"Evidence Action"},{"issue":"5","key":"10.1016\/j.jtct.2026.03.040_bib0017","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1086\/511640","article-title":"Measurement of adult antibacterial drug use in 130 US hospitals: comparison of defined daily dose and days of therapy","volume":"44","author":"Polk","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"7","key":"10.1016\/j.jtct.2026.03.040_bib0018","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofae398","article-title":"Chimeric antigen receptor T-cell postinfusion fever: infection profile, clinical parameters, and biomarkers trends to assist antibiotic stewardship","volume":"11","author":"Peyrony","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jtct.2026.03.040_bib0019","series-title":"Paper presented at: Proceedings of the Immunocompromised Host Society Meeting; 2023\/04","article-title":"The burden and outcomes of neutropenic fever following current-era treatment regimens for acute leukaemia and allogeneic haematopoietic cell transplant","author":"Douglas","year":"2023"},{"issue":"4","key":"10.1016\/j.jtct.2026.03.040_bib0020","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000858","article-title":"Identifying early infections in the setting of CRS with routine and exploratory serum proteomics and the HT10 score following CD19 CAR-T for relapsed\/refractory B-NHL","volume":"7","author":"Rejeski","year":"2023","journal-title":"Hemasphere"},{"key":"10.1016\/j.jtct.2026.03.040_bib0021","unstructured":"Keri VC, Monday LM, Ramakrishna JM, et al. Infections following chimeric antigen receptor T cell therapy: 2018\u20132022. Transplant Infect Dis. n\/a(n\/a):e14376."},{"issue":"4","key":"10.1016\/j.jtct.2026.03.040_bib0022","doi-asserted-by":"crossref","first-page":"978","DOI":"10.3324\/haematol.2019.238634","article-title":"Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma","volume":"106","author":"Logue","year":"2021","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.jtct.2026.03.040_bib0023","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-020-00346-7","article-title":"Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma","volume":"10","author":"Wudhikarn","year":"2020","journal-title":"Blood Cancer J"},{"issue":"4","key":"10.1016\/j.jtct.2026.03.040_bib0024","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/s41591-022-01702-9","article-title":"Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy","volume":"28","author":"Smith","year":"2022","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.jtct.2026.03.040_bib0025","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/s41591-023-02234-6","article-title":"A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy","volume":"29","author":"Stein-Thoeringer","year":"2023","journal-title":"Nat Med"},{"issue":"11","key":"10.1016\/j.jtct.2026.03.040_bib0026","doi-asserted-by":"crossref","first-page":"708.e701","DOI":"10.1016\/j.jtct.2023.08.013","article-title":"Early antibiotic deescalation and discontinuation in patients with febrile neutropenia after cellular therapy: a single-center prospective unblinded randomized trial","volume":"29","author":"Ram","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"10.1016\/j.jtct.2026.03.040_bib0027","doi-asserted-by":"crossref","first-page":"59","DOI":"10.46989\/001c.94105","article-title":"Early de-escalation of antibiotic therapy in hospitalized cellular therapy adult patients with febrile neutropenia","volume":"6","author":"Lucena","year":"2024","journal-title":"Clin Hematol Int"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726002563?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726002563?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T19:34:41Z","timestamp":1783193681000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636726002563"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":27,"alternative-id":["S2666636726002563"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2026.03.040","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Infections in the First 30 Days after Chimeric Antigen Receptor T-Cell Therapy in Patients Not Receiving Fluoroquinolone Prophylaxis","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2026.03.040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of American Society for Transplantation and Cellular Therapy.","name":"copyright","label":"Copyright"}]}}